Additionally, the implications of sFlt-1 are not only confined to the placenta, but these effects can also be observed in organs with high VEGF expression, like the kidneys and liver, possibly contributing to clinical presentation of systemic complications of preeclampsia [29, 30]. Here, VEGFA is linked to preeclampsia.